Overview

Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes

Status:
Completed
Trial end date:
2021-07-09
Target enrollment:
Participant gender:
Summary
To test for a difference in the pharmacokinetics (PK) and pharmacodynamics (PD) of teriparatide (PTH 1-34), between healthy male and female volunteers matched to military recruits in training.
Phase:
Phase 3
Details
Lead Sponsor:
Norfolk and Norwich University Hospitals NHS Foundation Trust
University of East Anglia
Collaborators:
Ministry of Defence, United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust
University of East Anglia
Treatments:
Teriparatide